Search
Search
Close this search box.

Clever Leaves Partners With FoliuMed to Import Colombian Cannabis EU-GMP Bulk Extracts Into Germany

A SUPPLY agreement between cannabis operators Clever Leaves and FoliuMed allows for the exportation of pharmaceutical grade cannabis bulk extracts from Colombia to Germany.

Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, has signed a one-year international sales agreement with German- Colombian operator FoliuMed Holdings (“FoliuMed”) and its German manufacturing partner, Fidelio Healthcare (“Fidelio”). With access to three of Clever Leaves’ pharmaceutical grade bulk cannabis extracts, Fidelio will be ramping up production using Clever Leaves’ full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate.

With high production standards recognized domestically and abroad, including both Good Manufacturing Practices (GMP) certification from Colombia and European Union Good Manufacturing Practices (EU GMP) certification from Europe, Clever Leaves’ Colombian pharmaceutical-grade cannabis will be utilized by Fidelio’s manufacturing and distribution teams to create affordable, orally administered gel capsules for consumption on a prescription basis by customers and patients in Australia, Europe and Latin America. Soft gel capsules are preferred by patients and doctors as they can be dosed more precisely than the market standard cannabis tinctures.

“Leveraging our Colombian operation to build and maintain relationships throughout the cannabinoid and pharmaceutical industry is incredibly important to us,” said Andrés Fajardo, President and incoming CEO of Clever Leaves in regard to the emerging partnership with FoliuMed. “We’re grateful for the opportunity to expand our international presence by partnering with FoliuMed and Fidelio, bringing Clever Leaves standard of production to a global scale.”

“FoliuMed and our manufacturing partner Fidelio are one of the five producers worldwide who manufacture cannabis soft gels for prescription medicines under EU-GMP”, said FoliuMed CEO Oliver Zugel. “We carefully chose Clever Leaves as our preferred raw material supplier for this highly strategic product range. As we are seeing increased customer interest for soft gels, we will expand our range of formulations and are looking forward to work with Clever Leaves in this endeavor.”     

Clever Leaves raw materials are shipped to FoliuMed’s German operation near Frankfurt where they are processed into soft gels at Fidelio’s EU-GMP contract manufacturing site and delivered to a leading Australian customer in the first quarter of 2022. With Clever Leaves recently making headlines as the first to export raw THC flower from Portugal to the U.S., and with this latest international agreement, Clever Leaves continues to demonstrate its ability to expand its distribution globally, meeting the highest standards required both by Germany, Australia and the European Union.

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?